27.5 C
Vientiane
Monday, September 22, 2025
spot_img
Home Blog Page 70

NYSE Content Advisory: Pre-Market Update + S&P comes off best week since August

NEW YORK, Sept. 15, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

NYSE Content Advisory: Pre-Market Update + S&P comes off best week since August

Ashley Mastronardi delivers the pre-market update on September 15th

  • Equities are higher Monday morning after a winning week on Wall Street. The S&P 500 recorded its best week since Early August with a gain of 1.6%. The DOW also snapped a losing streak.
  • Investors will be monitoring the latest with Nvidia after China says the firm violated an anti-monopoly law. This week’s activity will be dominated by the Federal Reserve with the central bank to deliver its next policy decision.
  • The Fed’s decision on interest rates will draw headlines, but investors will be keeping a close eye on other data points as well. The Empire State Manufacturing Index was released ahead of todays open.

Opening Bell
Deutsche Bank (NYSE: DB) celebrates Hispanic Heritage Month

Closing Bell
Union Pacific (NYSE: UNP) celebrates the company’s 155th anniversary of listing

Click here to download the NYSE TV App

 

Video – https://mma.prnasia.com/media2/2772918/NYSE_Market_Update_Sept_15.mp4

 

 

 

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

  • BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen’s industry-leading DEL technology platform, highlighting the value of DEL to accelerate innovative drug development.
  • The initiation of the BGE-102 Phase 1 clinical study triggers a milestone payment to HitGen.

CHENGDU, China, Sept. 15, 2025 /PRNewswire/ — Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”, SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. (“BioAge”, NASDAQ: BIOA), a clinical-stage biotechnology company based in Emeryville, CA, USA, on the initiation of a Phase 1 clinical study of BGE-102, a novel, potent NLRP3 inhibitor developed from a hit compound identified using HitGen’s industry-leading DEL technology platform. The event triggers an undisclosed milestone payment to HitGen under the collaboration agreement between the two companies.

BGE-102 is a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration being developed initially for the treatment of obesity. NLRP3 is a key driver of age-related inflammation that has been implicated in a broad range of diseases, including neurodegenerative conditions and cardiovascular disease as well as metabolic disorders such as obesity. BioAge identified NLRP3 as a therapeutic target for metabolic and age-related diseases and sought to develop novel inhibitors, leading to the successful collaboration with HitGen.

BGE-102 was developed by BioAge from hit compounds identified in a screen using HitGen’s DEL libraries under a collaboration agreement between the parties. In April 2021, the companies announced the successful identification of promising hit molecules. In February 2024, the companies further detailed their research collaboration outcome in a joint publication in Bioorganic & Medicinal Chemistry Letters, entitled “The discovery of novel and potent indazole NLRP3 inhibitors enabled by DNA-encoded library screening”. The collaboration has also resulted in joint patent filings covering the structurally novel compounds discovered through the DEL screening process. BioAge and HitGen continue to collaborate on additional drug lead discovery programs for other novel targets using HitGen’s DEL platform.

Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen Inc., stated: “We extend our congratulations to the BioAge team on this exciting progress. The advancement of BGE-102 into clinical studies not only validates the power of HitGen’s DEL platform to discover novel small molecules against challenging targets, but also reinforces the value of our partnership model. We look forward to continuing our collaboration and following the development of this promising candidate.”

“We’re excited to reach this important clinical milestone with BGE-102,” said Kristen Fortney, PhD, CEO and co-founder of BioAge. “HitGen’s DEL platform helped us identify structurally distinct NLRP3 inhibitors with a novel binding site and strong potency and brain penetration. Our collaboration demonstrates the value of combining HitGen’s cutting-edge screening technology with insights from human aging biology to advance potentially transformative treatments for metabolic diseases.”

HitGen is a world leader in the development of DEL technology and applications to early-stage small molecule drug discovery. Its platform includes over 1.2 trillion small molecules generated by the DEL technology, and the efficiency of the screening process has made it possible for HitGen to enable drug discovery projects for many organizations around the world.

About HitGen Inc.

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Meanwhile, we are developing a DEL+AI+Automated DMTA (Design-Make-Test-Analyze) molecular optimization platform to accelerate the discovery and optimization process of preclinical candidate compounds. Through our diverse and flexible business models, we have built up collaboration partnerships with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.

About BioAge Labs, Inc.

BioAge (NASDAQ: BIOA) is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company’s lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity. BGE-102 has demonstrated significant weight loss in preclinical models both as monotherapy and in combination with GLP-1 receptor agonists. A Phase 1 SAD/MAD trial of BGE-102 is underway, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

AMPLIFON: -42% DIRECT EMISSIONS AND -25% INDIRECT GREENHOUSE GAS EMISSIONS BY 2030

MILAN, Sept. 15, 2025 /PRNewswire/ — Amplifon, a global leader in hearing solutions and services, is launching its climate strategy validated by the Science Based Targets Initiative (SBTi) to reduce greenhouse gas emissions and contribute to achieving the goals of the 2015 Paris Agreement to counteract climate change.

The strategy, Listening to our Planet,” specifically calls for a 42% reduction in the company’s direct greenhouse gas emissions (Scope 1 and 2) by 2030 compared to 2023. Over the same period, the company has committed to reducing indirect Scope 3 emissions by 25%, deriving from purchased goods and services, capital goods, fuel and energy related activities, upstream transportation and distribution, employee commuting, upstream leased assets, use of sold products and franchises. The plan also stipulates that, by 2030, 44.36% of its suppliers in terms of emissions related to purchased goods and services will have greenhouse gas emission reduction targets based on climate science.

The launch of a scientifically validated climate strategy,” comments Amplifon CEO Enrico Vita, “represents a further step forward in the process of fully integrating ESG factors into our business. Making concrete commitments to reduce our direct and indirect emissions in the medium term is in line with the sustainability plan we launched last year with 20 concrete and measurable targets for 2026, 2028, and 2030 in the areas of products and services, ethics and environmental responsibility, people, and communities. We want to continue to grow in an increasingly responsible and sustainable manner.”

The Science Based Targets Initiative, a non-profit organization launched in 2015 by a coalition of international actors such as CDP, UN Global Compact, World Resources Institute, WWF, and We Mean Business Coalition, supports companies in setting greenhouse gas emission reduction targets consistent with the latest scientific evidence on climate change.

Amplifon’s Corporate Website 

Amplifon’s Sustainability Plan

New Climate Strategy

Amplifon

Amplifon, hearing care global leader, empowers people to rediscover all the emotions of sound. Amplifon’s over 20,000 people worldwide strive every day to understand the unique needs of every customer, delivering exclusive, innovative and highly personalized products and services, to ensure everyone the very best solution and outstanding experience. The Group, with annual revenues of over 2.4 billion euros, operates through a network of over 10,000 points of sale in 26 Countries and 5 continents.

 

Corporate Communication

Salvatore Ricco

M. 39 335 770 9861

salvatore.ricco@amplifon.com

 

 

LabConnect and OmniScience to Deliver First Agentic AI Solution for Real-Time Clinical Trial Lab Insights

Together we’re unlocking the true potential of clinical trial lab data, bringing faster insights, smarter decisions, and better outcomes.

JOHNSON CITY, Tenn. and HOUSTON, Sept. 15, 2025 /PRNewswire/ — LabConnect, a leading global provider of central laboratory services today announced plans to form a strategic collaboration with OmniScience, the AI company behind Vivo, the first agentic AI control tower for clinical trials. Together, they will deliver the industry’s first AI-driven solution enabling sponsors to gain intelligent, real-time insights from clinical trial lab data.

LabConnect and OmniScience logos
LabConnect and OmniScience logos

Faster Decisions and Smarter Oversight with LabConnect + Vivo 
Clinical trial lab data is often siloed, complex, and delayed. This causes slow decision-making and introduces risk. By combining LabConnect’s expertise in central lab testing and data management with OmniScience’s Vivo platform, trial sponsors can now unify fragmented lab datasets, automate oversight, and surface risk signals that accelerate trial timelines and improve outcomes.

About Vivo: Real-Time Intelligence for Clinical Trials, Purpose-Built for Lab Data
Vivo is an AI-native clinical trial intelligence platform that transforms how teams interact with data across the clinical development lifecycle. Designed to unify disparate sources and deliver real-time insights, Vivo functions as a control tower equipping clinical, operational, safety, and data science teams with the clarity to act faster and more confidently. Vivo-Lab, a specialized implementation of Vivo, brings this same intelligence to laboratory data. Vivo-Lab streamlines lab workflows by surfacing critical trends, anomalies, and site-level discrepancies as they happen, helping teams move from reactive to proactive oversight in one of the most complex and variable data streams in clinical research.

Transforming Lab Data into Real-Time Action
“Our mission at OmniScience is to help trial teams see and act faster,” said Angela Holmes, CEO and Co-Founder of OmniScience. “Partnering with LabConnect extends that vision by transforming lab data into real time actionable intelligence that sponsors can trust.”

Wes Wheeler, CEO of LabConnect, added: “At LabConnect, we’re committed to helping sponsors unlock the full potential of their lab data. By integrating OmniScience’s transformative AI, we are shifting lab results from static reports into dynamic, actionable intelligence. Together, we’re giving clinical operations teams the speed, agility, and precision they need to make smarter decisions, improve trial efficiency, and bring therapies to patients faster.”

The partnership underscores both organizations’ commitment to innovation in clinical development, bringing together LabConnect’s technology-driven laboratory operations and OmniScience’s AI-native approach to trial intelligence.

About LabConnect
LabConnect, LLC is the leading provider of Central Laboratory Services, FSP and Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases.

LabConnect’s unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets, and extensive specialized testing expertise means that drug development companies can rely on one provider for all their central laboratory service needs.

Learn more at www.labconnect.com and follow on LinkedIn.

About OmniScience
OmniScience is a leading AI company transforming clinical development with Vivo, the first agentic AI control tower purpose-built for clinical trials. Built by a team of PhD-trained clinical data scientists, Vivo unifies fragmented trial data, applies intelligent automation, and delivers real-time, explainable insights that help sponsors reduce costs, shorten timelines, and increase trial success rates. Award winning and recognized by programs including Johnson & Johnson’s JLABS, NVIDIA Inception, and Google Cloud for AI, OmniScience is pioneering a new era of clinical trial intelligence to accelerate the delivery of life-changing treatments to patients.

 

BioCatch Receives Frost & Sullivan’s 2025 Global Competitive Strategy Leadership Recognition for Excellence in Fraud Detection and Prevention

This recognition underscores BioCatch’s strategic focus on fraud detection and prevention for the BFSI industry leveraging behavioral biometrics and customer collaboration

SAN ANTONIO, Sept. 15, 2025 /PRNewswire/ — Frost & Sullivan is pleased to announce that BioCatch, which prevents financial crime by recognizing patterns in human behavior, has earned the 2025 Global Competitive Strategy Leadership Recognition in the BFSI fraud detection and prevention (FDP) industry for its outstanding achievements in strategy execution, innovation, and customer impact. This recognition highlights BioCatch’s consistent leadership in combating fraud, strengthening its market position, and delivering customer-centric innovation in an evolving threat landscape.

Frost & Sullivan’s evaluation focused on key areas of strategic effectiveness and execution. BioCatch demonstrates excellence by aligning its strategic initiatives with market demands, and by executing these strategies efficiently, consistently, and at scale—resulting in a distinct competitive advantage. “BioCatch’s behavioral biometric assets, targeted market approach, and customer collaboration are strategic advantages. Its deployment at more than 30 of the top 100 global banks shows the success of its strategy,” said Deepali Sathe, Senior Industry Analyst at Frost & Sullivan.

BioCatch’s long-term strategy is centered on fraud detection and prevention in the financial services sector. The company’s continuous investment in research and development, supported by customer feedback, has helped it address new security challenges and expand its presence in global markets.

Innovation is fundamental to BioCatch’s strategy, which is evident in the more than 90 patents it owns. The company’s fraud detection and prevention platform utilizes behavioral intelligence to effectively mitigate advanced forms of fraud such as social engineering scams, account takeover (ATO), mule accounts, and automated bot attacks.

“This recognition is a testament to our customers, who inspire us to continually push the boundaries of fraud prevention,” BioCatch Chief Strategy Officer Amelia Ahlgren said. “We are laser-focused on the financial services industry, where we deeply understand our customers’ challenges and partner with them to deliver innovation that makes banking safer every day. By aligning our strategy with their needs, we ensure our solutions drive measurable impact and lasting consumer trust.”

BioCatch demonstrates a strong dedication to customer success, which reinforces its leadership in the market. The company facilitates efficient implementation through a modular platform, offers flexible deployment solutions, and upholds exceptional service availability. Through direct engagement with leading global banks and a partner-led delivery model for the mid-market sector and direct engagement with leading global banks, BioCatch ensures scalable and effective value delivery across a broad range of market segments.

Frost & Sullivan commends BioCatch for setting a high standard in competitive strategy, execution, and market responsiveness. The company’s vision, innovation pipeline, and customer-first culture are shaping the future of fraud detection and prevention in the BFSI industry and driving tangible results at scale.

Each year, Frost & Sullivan presents the Competitive Strategy Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition highlights forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

Frost & Sullivan Best Practices Recognition
Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.

Contact us: Start the discussion.

Contact:
Ashley Shreve
E: ashley.weinkauf@frost.com 

About BioCatch
BioCatch prevents financial crime by recognizing patterns in human behavior, continuously collecting more than 3,000 anonymized data points – keystroke and mouse activity, touch screen behavior, physical device attributes, and more – as people interact with their digital banking platforms. With these inputs, BioCatch’s machine-learning models reveal patterns in user behavior and provide device intelligence that, together, distinguish the criminal from the legitimate. The company’s Customer Innovation Board – an industry-led initiative in partnership with American Express, Barclays, Citi Ventures, HSBC, National Australia Bank, and others – collaborates to pioneer innovative ways of leveraging customer relationships for improved fraud detection. Today, more than 30 of the world’s largest 100 banks and 287 total financial institutions deploy BioCatch solutions, analyzing 16 billion user sessions per month and protecting more than 532 million people on more than 1.6 billion devices around the world from fraud and financial crime.

Media/PR contact:
Mac King E: Mac.King@BioCatch.com

 

EmeTerm Wearable Device Under Clinical Study at Ohio State Wexner Medical Center Shows Promise for Chronic Nausea Patients

VANCOUVER, BC, Sept. 15, 2025 /PRNewswire/ — WAT Medical Enterprise Ltd. is proud to announce that its innovative anti-nausea wristband, EmeTerm, has made significant progress in alleviating nausea and vomiting among patients suffering from chronic gastric disorders. A clinical study currently underway at The Ohio State University Wexner Medical Center is evaluating the device’s impact on individuals with moderate to severe chronic nausea, a condition that affects millions worldwide.

A Growing Unmet Medical Need
Chronic nausea and vomiting remain challenging to treat. According to the American College of Gastroenterology (ACG), up to 12% of the U.S. population may suffer from functional dyspepsia and related chronic gastric disorders, with nausea being one of the most debilitating symptoms (ACG Clinical Guideline, 2022). Standard antiemetic medications often carry side effects such as fatigue, dizziness, and constipation, limiting long-term use.

Globally, the antiemetic drug market was valued at USD 4.8 billion in 2022 and is projected to grow at a CAGR of 6.2% through 2030 (Grand View Research, 2023). The demand for safe, non-invasive, drug-free alternatives is steadily rising.


How EmeTerm Works
EmeTerm employs transcutaneous electrical acustimulation (TEAS) technology. The device delivers gentle electrical pulses to the median nerve on the wrist, modulating neural signals between the gut and the brain. This mechanism helps reduce nausea and prevent vomiting—without the side effects typically associated with pharmacological treatments.

Clinical evidence supports EmeTerm efficacy of reduce nausea and prevent vomiting. A multicenter randomized controlled trial demonstrated that EmeTerm significantly reduced the incidence of postoperative nausea and vomiting (PONV) in patients undergoing hysteroscopic surgery (Wang, 2022).

Unlike medications that must be taken regularly, EmeTerm can be worn on-demand, making it a practical tool for individuals managing unpredictable or chronic episodes of nausea. EmeTerm is already FDA-cleared as an over-the-counter device for nausea relief, including motion sickness and pregnancy-related nausea.

Promising Strides at Ohio State University

Ohio State University hopes to conduct research on using modern medical technologies to control chronic gastrointestinal diseases. Since 2023, The Ohio State University Wexner Medical Center has been conducting a clinical study to evaluate the potential of EmeTerm as a supportive therapy for chronic gastrointestinal disorders. 

This trial marks a critical step in evaluating its potential as a therapeutic adjunct for chronic gastrointestinal conditions. Final study results are anticipated in the coming months. Recent results show that nearly 50% of patients with moderate to severe nausea experienced meaningful relief, while approximately 30% of participants suffering from vomiting also reported improvement.

The study, launched in 2023 and expected to conclude in 2026, is closely monitoring patients with conditions such as gastroparesis, chronic gastritis, and other gastrointestinal disorders. Researchers are tracking the device’s effectiveness across a wide spectrum of gastric diseases to confirm its benefits for a broad patient population.

References
1. American College of Gastroenterology. (2022). ACG clinical guideline: Gastroparesis, functional dyspepsia, and chronic nausea and vomiting disorders. The American Journal of Gastroenterology, 117(7), 1197–1220. https://doi.org/10.14309/ajg.0000000000001835

2. Grand View Research. (2023). Antiemetic drugs market size, share & trends analysis report by drug type, by distribution channel, by region, and segment forecasts, 2023–2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/antiemetic-drugs-market

3. Wang, N., et al. (2022). Wearable transcutaneous electrical acupoint stimulation bracelet for prevention of postoperative nausea and vomiting in patients undergoing hysteroscopic surgery: a randomised controlled trial. British Journal of Anaesthesia, 129(4), e85-e87.

4. www.watmedical.com 

5. www.emeterm.com 

FEELINGIRL Honored at MUSE Design Awards for Redefining Post-Surgery Shapewear

RANCHO CUCAMONGA, Calif., Sept. 15, 2025 /PRNewswire/ — FEELINGIRL, a brand renowned for its technology-driven shapewear, once again took center stage with the FEELINGIRL Bra collection. Dedicated to enhancing women’s confidence, FEELINGIRL is committed to creating comfortable, close-fitting lingerie designed for women of all ages and life stages. With its latest FeelCare collection, the brand has been honored with the Silver Award in the Fashion Design category at the prestigious MUSE Design Awards.

FEELINGIRL Honored at MUSE Design Awards for Redefining Post-Surgery Shapewear
FEELINGIRL Honored at MUSE Design Awards for Redefining Post-Surgery Shapewear

The MUSE Design Awards, one of the most prestigious honors in the global design community, celebrates innovation and excellence across multiple disciplines. This year’s competition attracted nearly 10,000 entries from around the world, with evaluation criteria spanning creativity, functionality, social value, and breakthroughs in aesthetics.

The award-winning FeelCare collection represents the culmination of the brand’s long-standing commitment to fabric technology innovation for the FEELINGIRL Bra collection. Trusted by consumers, the FEELINGIRL Bra collection has earned recognition for comfort, functional materials, and technology-driven shaping. The brand invests in textile research and development, advancing support, breathability, and skin-friendliness. With years of expertise in everyday lingerie, FEELINGIRL has transferred these innovations to the demanding field of post-surgery recovery, creating a milestone collection that combines medical functionality with human-centered design.

The FEELINGIRL FeelCare post-surgery shapewear collection is a product line designed with women’s recovery needs as its primary focus. Developed with ergonomic structure, intelligent support systems, and advanced functional fabrics, the collection provides tailored solutions for the unique challenges women face during post-surgical recovery. Two core products anchor the collection: a post-surgery bra and shaping pants. Together, they target the chest and waist-abdominal regions to deliver reliable support and contouring, balancing practicality with comfort across various daily scenarios, from early recovery to commuting or at-home wear.

The post-surgery bra stands out for its thoughtful details and focus on both comfort and support. Its full-coverage, wire-free construction avoids padded cups while offering a stable structure, minimizing pressure and movement during sensitive recovery stages. Bust-enhancing panels subtly lift and shape, while the hem features the brand’s exclusive logo elastic band that prevents sagging and ensures secure contouring. Inside, a molding process creates space for a seamless, natural bust profile. Wide, adjustable shoulder straps reduce shoulder strain while enhancing back contours. For convenience, especially important during recovery, the bra incorporates a front-center three-row hook design, allowing easier dressing and a better fit for different body types.

Complementing the bra, the shaping pants emphasize waist and abdominal support with a high-waist, double-layer compression structure. This design stabilizes the waistline, flattens the stomach, and defines contours, while built-in lifting panels naturally enhance the hips to create a seamless, sculpted silhouette. Boning in the back waist prevents rolling and supports lumbar stability, while a front zipper-and-hook system ensures secure wear. A separate crotch zipper enhances practicality, recognizing the everyday needs of women in recovery.

Beyond individual product features, the FeelCare collection distinguishes itself through structural optimization rooted in multidimensional human body curve data. By applying zoned compression technology, the garments provide precise shaping and support for the waist, abdomen, and hips. A 360-degree four-way stretch wrap enhances comfort, while the front waist-abdomen incorporates a shaping mesh layer to create a three-layer contouring system. These innovations together form a collection that merges science-driven precision with user-focused comfort.

In a competitive global field, the FeelCare collection stood out for its ability to address women’s post-surgery recovery needs with products that respect both function and dignity. With the FeelCare collection, FEELINGIRL has demonstrated that shapewear can serve as more than a functional garment; it can become a meaningful part of recovery and confidence-building. The award signals a significant step for the brand on the global stage, reaffirming its commitment to advancing women’s health through thoughtful design and innovation.

For more details, please visit: https://feelingirl.com/ or search “FEELINGIRL” on Amazon.   

MAS9 Brings Digital Transformation to U.S. Martial Arts Schools With AI-Powered SaaS Platform

SEOUL, South Korea , Sept. 15, 2025 /PRNewswire/ — South Korean startup MAS9 has made a rapid entry into the U.S. Taekwondo market, onboarding more than 100 schools within a month of launching its paid SaaS platform. The company’s solution is the first business-to-business-to-consumer (B2B2C) digital management system designed specifically for martial arts schools in the United States.

The platform replaces manual administrative tasks—such as tuition collection, overdue payment reminders, and attendance tracking—with a fully automated system. Parents and students also benefit from real-time access to class schedules, training progress, and instructor feedback via MAS9’s dedicated mobile app and website.

Building on this momentum, MAS9 will introduce a one-click e-commerce feature in January 2026, giving school owners a new revenue opportunity. Without carrying inventory, owners will be able to launch online shops and sell uniforms, equipment, and merchandise directly to students and parents through the platform. The U.S. Taekwondo merchandise market is estimated at around $400 million, and MAS9’s upcoming feature is designed to help school operators capture this demand more effectively..

“MAS9 provides both operational efficiency and financial upside for school owners, which explains the strong adoption we’ve seen in such a short time,” said Dongho Ryoo, CEO of MAS9 USA. He added that the company has been able to accelerate adoption by rapidly incorporating feedback from U.S. school operators, leveraging more than two decades of local market experience.

Looking forward, MAS9 plans to integrate artificial intelligence into its system, with features such as student retention analytics, personalized training content, and financial forecasting tools.

Sang-Youb Lee, CEO of MAS9 said the company’s long-term ambition is to build a global Taekwondo business platform. “With 700,000 schools, 1.5 million instructors, and 80 million practitioners worldwide, Taekwondo represents a massive opportunity. Our early success in the U.S. validates our strategy and lays the groundwork for international expansion.”